Suvorexant
Overview
Suvorexant is a dual orexin receptor antagonist used for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. It works by inhibiting the action of orexins, neuropeptides that play a role in promoting wakefulness.
API suppliers (5)
Suppliers of Suvorexant evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
Country recorded for 4 of 5 suppliers.
4 of 5 hold a GMP certificate on record in the EU or UK registers
- Maithri Laboratories Private LimitedIndia1 active DMF GMP on record
- Zydus Lifesciences LimitedIndia1 active DMF GMP on record
- Alembic Pharmaceuticals LimitedIndia1 active DMF GMP on record
- APITORIA PHARMA PRIVATE LTDIndia1 active DMF GMP on record
- BIOPHORE INDIA PHARMACEUTICALS PVT LTD1 active DMF
Patent & exclusivity (US)
Per the FDA Orange Book (4 approved US products), the latest listed US patent on Suvorexant expires 29 May 2033. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Suvorexant? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.